Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.

Zhai Y, Zhang Y, Nan K, Liang X.

Oncol Lett. 2017 May;13(5):3233-3238. doi: 10.3892/ol.2017.5829. Epub 2017 Mar 8.

2.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

3.

The ISG15-specific protease USP18 regulates stability of PTEN.

Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E.

Oncotarget. 2017 Jan 3;8(1):3-14. doi: 10.18632/oncotarget.13914.

4.

Effects of the IGF-1/PTEN/Akt/FoxO signaling pathway on male reproduction in rats subjected to water immersion and restraint stress.

Huang P, Zhou Z, Shi F, Shao G, Wang R, Wang J, Wang K, Ding W.

Mol Med Rep. 2016 Dec;14(6):5116-5124. doi: 10.3892/mmr.2016.5880. Epub 2016 Oct 24.

5.

The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.

Wan G, Pehlke C, Pepermans R, Cannon JL, Lidke D, Rajput A.

Cell Death Discov. 2015 Oct 19;1:15044. doi: 10.1038/cddiscovery.2015.44. eCollection 2015.

6.

The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells.

Guo XR, Yang ZS, Tang XJ, Zou DD, Gui H, Wang XL, Ma SN, Yuan YH, Fang J, Wang B, Zhang L, Sun XY, Warnock GL, Dai LJ, Tu HJ.

Oncotarget. 2016 Aug 23;7(34):55529-55542. doi: 10.18632/oncotarget.10835.

7.

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

Am Soc Clin Oncol Educ Book. 2016;35:e235-45. doi: 10.14694/EDBK_159244. Review.

8.

PTEN-mRNA engineered mesenchymal stem cell-mediated cytotoxic effects on U251 glioma cells.

Guo XR, Hu QY, Yuan YH, Tang XJ, Yang ZS, Zou DD, Bian LJ, Dai LJ, Li DS.

Oncol Lett. 2016 Apr;11(4):2733-2740. Epub 2016 Mar 1.

9.

CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc.

Pu H, Zheng Q, Li H, Wu M, An J, Gui X, Li T, Lu D.

Oncotarget. 2015 Dec 1;6(38):40775-98. doi: 10.18632/oncotarget.5805.

10.

The human parasite Leishmania amazonensis downregulates iNOS expression via NF-κB p50/p50 homodimer: role of the PI3K/Akt pathway.

Calegari-Silva TC, Vivarini ÁC, Miqueline M, Dos Santos GR, Teixeira KL, Saliba AM, Nunes de Carvalho S, de Carvalho L, Lopes UG.

Open Biol. 2015 Sep;5(9):150118. doi: 10.1098/rsob.150118.

11.

Focus on PTEN Regulation.

Bermúdez Brito M, Goulielmaki E, Papakonstanti EA.

Front Oncol. 2015 Jul 27;5:166. doi: 10.3389/fonc.2015.00166. eCollection 2015. Review.

12.

Missense mutation in the PTEN promoter of a patient with hemifacial hyperplasia.

Yamazaki K, Eng C, Kuznetsov SA, Reinisch J, Yamashita DD, Walker J, Cheung C, Robey PG, Yen SL.

Bonekey Rep. 2015 Jul 29;4:654. doi: 10.1038/bonekey.2015.21. eCollection 2015.

13.

Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Kardos GR, Robertson GP.

Pigment Cell Melanoma Res. 2015 Sep;28(5):501-19. doi: 10.1111/pcmr.12391. Review.

14.

The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.

Ejeskär K, Vickes O, Kuchipudi A, Wettergren Y, Uv A, Rotter Sopasakis V.

PLoS One. 2015 May 29;10(5):e0127497. doi: 10.1371/journal.pone.0127497. eCollection 2015.

15.

PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.

Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Jun;14(6):1466-75. doi: 10.1158/1535-7163.MCT-14-1077. Epub 2015 Apr 1.

16.

Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.

Wang H, Zhang P, Lin C, Yu Q, Wu J, Wang L, Cui Y, Wang K, Gao Z, Li H.

PLoS One. 2015 Feb 25;10(2):e114250. doi: 10.1371/journal.pone.0114250. eCollection 2015.

17.

Analysis of intracellular PTEN signaling and secretion.

Hodakoski C, Fine B, Hopkins B, Parsons R.

Methods. 2015 May;77-78:164-71. doi: 10.1016/j.ymeth.2014.11.008. Epub 2014 Nov 15. Review.

18.

Phospholipid-binding sites of phosphatase and tensin homolog (PTEN): exploring the mechanism of phosphatidylinositol 4,5-bisphosphate activation.

Wei Y, Stec B, Redfield AG, Weerapana E, Roberts MF.

J Biol Chem. 2015 Jan 16;290(3):1592-606. doi: 10.1074/jbc.M114.588590. Epub 2014 Nov 27.

19.

Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.

Blum JS, Weller CE, Booth CJ, Babar IA, Liang X, Slack FJ, Saltzman WM.

Drug Deliv Transl Res. 2011 Oct 1;1(5):383-394.

20.

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, Frazier K, Ng S, Smith A, Verhagen J, Haznedar J, Huh K, Iwanowicz E, Xin X, Menezes D, Merritt H, Lee I, Wiesmann M, Kaufman S, Crawford K, Chin M, Bussiere D, Shoemaker K, Zaror I, Maira SM, Voliva CF.

ACS Med Chem Lett. 2011 Aug 26;2(10):774-9. doi: 10.1021/ml200156t. eCollection 2011 Oct 13.

Supplemental Content

Support Center